Keiretsu Capital
Keiretsu Capital invests in emerging companies alongside angel investors, providing additional round and follow-on capital. It supports portfolio companies by helping them connect with syndicate partners, venture capitalists, corporate investors and public markets.
Facts
- HQ
- Seattle, WA, US
- Founded
- 2013
- Employees
- 2–10
Is this your organization? Claim it
Healionics Raises $5.5M to Complete Human Trial of STARgraft Artificial Blood Vessel for Dialysis Patients
Healionics, a Seattle-based medical tech company, raised $5.5 million to complete human trials and pursue regulatory approval for its STARgraft artificial blood vessel designed for dialysis patients. The STARgraft aims to provide a durable vascular access solution resistant to blockages and infections that commonly affect dialysis patients.
Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch
Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.
LumiThera raises $14M to complete LIGHTSITE III trial and pursue U.S. clearance for Valeda
LumiThera, a Poulsbo, Wash. medical device startup, raised $14 million to finish enrollment in its LIGHTSITE III U.S. trial and seek U.S. regulatory clearance for Valeda, a photobiomodulation device for dry age-related macular degeneration already approved in the EU.
See all 5 stories, episodes and videos about Keiretsu Capital.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events